Predictors of Successful Cardioversion with Vernakalant in Patients with Recent‐Onset Atrial Fibrillation

BACKGROUND: Vernakalant is a novel atrial‐selective antiarrhythmic drug able to convert recent‐onset atrial fibrillation (AF) with reportedly low proarrhythmic risk. Successful cardioversion predictors are largely unknown. We sought to evaluate clinical and electrocardiographic predictors of cardiov...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Noninvasive Electrocardiol
Asıl Yazarlar: Mochalina, Natalia, Juhlin, Tord, Öhlin, Bertil, Carlson, Jonas, Holmqvist, Fredrik, Platonov, Pyotr G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931769/
https://ncbi.nlm.nih.gov/pubmed/25040826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/anec.12178
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller